

Ninian N Lang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1649083/publications.pdf>

Version: 2024-02-01

74
papers

2,245
citations

279487

23
h-index

233125

45
g-index

82
all docs

82
docs citations

82
times ranked

3268
citing authors

#	ARTICLE	IF	CITATIONS
1	The "other"™ big complication: how chronic kidney disease impacts on cancer risks and outcomes. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1071-1079.	0.4	16
2	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	1.0	213
3	Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEK Inhibitors. <i>JACC: CardioOncology</i> , 2022, 4, 1-18.	1.7	18
4	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2186-2199.	1.4	9
5	A multisystem, cardio-renal investigation of post-COVID-19 illness. <i>Nature Medicine</i> , 2022, 28, 1303-1313.	15.2	39
6	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021, 143, 516-525.	1.6	237
7	Effects of a Novel Nitroxyl Donor in Acute Heart Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	1.9	17
8	Cardiotoxic effects of angiogenesis inhibitors. <i>Clinical Science</i> , 2021, 135, 71-100.	1.8	46
9	Cardiovascular Oncologic Emergencies. , 2021, , 269-290.		0
10	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGM-HF. <i>Journal of the American Heart Association</i> , 2021, 10, e019238.	1.6	20
11	Reply. <i>JACC: CardioOncology</i> , 2021, 3, 166.	1.7	0
12	Haemodynamic effects of the nitroxyl donor cimlanod (BMS-986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1147-1155.	2.9	13
13	Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. <i>Circulation Research</i> , 2021, 128, 1040-1061.	2.0	59
14	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. <i>Clinical Science</i> , 2021, 135, 991-1007.	1.8	18
15	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1130.	3.0	114
16	Pulmonary thromboembolism in hospitalised patients with COVID-19: a retrospective national study of patients managed in critical care and ward environments in Scotland. <i>BMJ Open</i> , 2021, 11, e050281.	0.8	2
17	Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study. <i>EClinicalMedicine</i> , 2021, 38, 101030.	3.2	24
18	Abstract 44: VEGF Inhibitor-induced Vascular Dysfunction Is Ameliorated By PARP/TRPM2 Inhibition. <i>Hypertension</i> , 2021, 78, .	1.3	0

#	ARTICLE	IF	CITATIONS
19	EMPEROR-REDUCED reigns while EMPERIAL whimpers. <i>European Heart Journal</i> , 2021, 42, 711-714.	1.0	8
20	Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity. <i>Clinical Science</i> , 2021, 135, 2661-2663.	1.8	3
21	Cisplatin related cardiotoxicity – acute and chronic cardiovascular morbidity in a testicular cancer survivor. <i>Scottish Medical Journal</i> , 2020, 65, 24-27.	0.7	3
22	Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. <i>Journal of Hypertension</i> , 2020, 38, 257-265.	0.3	5
23	Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicular Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 443-455.	1.7	20
24	Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. <i>Cardiovascular Research</i> , 2020, 116, e152-e155.	1.8	8
25	MULTI-PARAMETRIC CARDIAC MAGNETIC RESONANCE MARKERS OF ANGIOGENESIS INHIBITOR-INDUCED CARDIOTOXICITY. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1672.	1.2	0
26	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. <i>Cardiovascular Research</i> , 2020, 116, 2185-2196.	1.8	31
27	Cardiotoxicity and myocardial hypoperfusion associated with anti-vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer. <i>European Journal of Heart Failure</i> , 2020, 22, 1276-1277.	2.9	12
28	Vascular toxicity associated with anti-angiogenic drugs. <i>Clinical Science</i> , 2020, 134, 2503-2520.	1.8	33
29	Abstract P1-13-02: Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data. , 2020, , .		0
30	Progressive Hypertension and Severe Left Ventricular Outflow Tract Obstruction. <i>Hypertension</i> , 2019, 74, 1216-1225.	1.3	2
31	Hypertension and Antiangiogenesis. <i>JACC: CardioOncology</i> , 2019, 1, 37-40.	1.7	4
32	Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. <i>European Journal of Heart Failure</i> , 2019, 21, 699-702.	2.9	7
33	Antihypertensive Drugs and Vascular Health. <i>Updates in Hypertension and Cardiovascular Protection</i> , 2019, , 585-605.	0.1	0
34	Vascular Biology of Cancer Chemotherapeutic Drugs. , 2019, , 259-268.		0
35	Adult Congenital Heart Disease and Radiation Exposure. <i>Circulation</i> , 2018, 137, 1346-1348.	1.6	5
36	Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. <i>Heart</i> , 2018, 104, 1995-2002.	1.2	51

#	ARTICLE	IF	CITATIONS
37	Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition. <i>Hypertension</i> , 2017, 70, 220-226.	1.3	76
38	Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus. <i>Open Heart</i> , 2017, 4, e000647.	0.9	19
39	Cardiovascular Complications from Cancer Therapy. , 2016, , 185-211.		0
40	Rotigaptide protects the myocardium and arterial vasculature from ischaemia reperfusion injury. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1037-1045.	1.1	15
41	Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus. <i>Open Heart</i> , 2016, 3, e000402.	0.9	27
42	Drug Treatment of Hypertension: Focus on Vascular Health. <i>Drugs</i> , 2016, 76, 1529-1550.	4.9	53
43	Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 974-982.	1.1	34
44	Vascular Complications of Cancer Chemotherapy. <i>Canadian Journal of Cardiology</i> , 2016, 32, 852-862.	0.8	158
45	Biomarkers of acute rejection following cardiac transplantation. <i>Biomarkers in Medicine</i> , 2014, 8, 815-832.	0.6	10
46	Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy. <i>Biomarkers in Medicine</i> , 2014, 8, 797-806.	0.6	1
47	The ease of use and reproducibility of the Alere [®] Heart Check System: a comparison of patient and healthcare professional measurement of BNP. <i>Biomarkers in Medicine</i> , 2014, 8, 791-796.	0.6	14
48	Emerging biomarkers for heart failure: an update. <i>Biomarkers in Medicine</i> , 2014, 8, 833-840.	0.6	4
49	UVA Irradiation of Human Skin Vasodilates Arterial Vasculature and Lowers Blood Pressure Independently of Nitric Oxide Synthase. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1839-1846.	0.3	213
50	Heart failure resistant to standard medical therapy. , 2014, , 209-226.		0
51	Quantitative myocardial inflammation assessed using a novel USPIO-Magnetic Resonance Imaging acquisition and analysis protocol. <i>Journal of Cardiovascular Magnetic Resonance</i> , 2013, 15, O114.	1.6	2
52	Effect of PS1 ⁶⁹⁷ , a Novel P ⁶⁹⁷ -Selectin Inhibitor, on Platelet ⁶⁹⁷ -Monocyte Aggregate Formation in Humans. <i>Journal of the American Heart Association</i> , 2013, 2, e006007.	1.6	26
53	Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers. <i>Journal of the American Heart Association</i> , 2013, 2, e000042.	1.6	82
54	Role of Asymmetric Methylarginine and Connexin 43 ⁴³ in the Regulation of Pulmonary Endothelial Function. <i>Pulmonary Circulation</i> , 2013, 3, 675-691.	0.8	19

#	ARTICLE	IF	CITATIONS
55	Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers. Journal of the American Heart Association, 2013, 2, e004267.	1.6	21
56	Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation. Journal of the Royal College of Physicians of Edinburgh, The, 2013, 43, 151-158.	0.2	3
57	Cardiology Symposium. Journal of the Royal College of Physicians of Edinburgh, The, 2013, 43, 159-160.	0.2	0
58	Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients With Acute Myocardial Infarction. Circulation: Cardiovascular Imaging, 2012, 5, 559-565.	1.3	148
59	Cardiac compression causing fatal acute ST-segment elevation myocardial infarction. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 883-885.	0.2	2
60	In Vivo Mononuclear Cell Tracking Using Superparamagnetic Particles of Iron Oxide. Circulation: Cardiovascular Imaging, 2012, 5, 509-517.	1.3	100
61	Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb. Heart and Vessels, 2012, 27, 179-185.	0.5	6
62	The role of ADMA in the regulation of pulmonary endothelial cell-to-cell communication, endothelial permeability and angiogenesis. Vascular Pharmacology, 2012, 56, 333-334.	1.0	0
63	Vascular PAR-1: Activity and Antagonism. Cardiovascular Therapeutics, 2011, 29, 349-361.	1.1	6
64	Current drug therapies used in the secondary prevention of MI. The Prescriber, 2010, 21, 22-45.	0.1	1
65	Urocortins in heart failure. Biochemical Pharmacology, 2010, 80, 289-296.	2.0	27
66	5.1 ENHANCED COMMUNICATION VIA GAP JUNCTIONS PROTECTS THE ENDOTHELIUM FROM ISCHAEMIA-REPERFUSION INJURY IN VIVO IN MAN. Artery Research, 2010, 4, 147.	0.3	0
67	Current drug therapies for the secondary prevention of MI. The Prescriber, 2008, 19, 14-25.	0.1	1
68	The vascular effects of rotigaptide in vivo in man. Biochemical Pharmacology, 2008, 76, 1194-1200.	2.0	18
69	Role of the Endothelium in the Vascular Effects of the Thrombin Receptor (Protease-Activated) Tj ETQq1 1 0.784314,rgBT /Overlock 101	1.2	25
70	Marked Impairment of Protease-Activated Receptor Type 1-Mediated Vasodilation and Fibrinolysis in Cigarette Smokers. Journal of the American College of Cardiology, 2008, 52, 33-39.	1.2	25
71	Vascular B1 Kinin Receptors in Patients With Congestive Heart Failure. Journal of Cardiovascular Pharmacology, 2008, 52, 438-444.	0.8	6
72	Chapter 3 Investigation of patients with suspected chronic heart failure. , 2008, , .		1

#	ARTICLE	IF	CITATIONS
73	Emerging Thrombotic Effects of Drug Eluting Stents. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 261-262.	1.1	12
74	Connexin 43 mediates endothelium-derived hyperpolarizing factor-induced vasodilatation in subcutaneous resistance arteries from healthy pregnant women. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H1026-H1032.	1.5	50